Researchers at the University of California, Davis have developed a bioengineered, RNA-based treatment for advanced liver cancer and hepatocellular carcinoma (HCC).
Currently, hepatocellular carcinoma (HCC) is a leading and increasingly common cause of cancer-related deaths. Although surgical resection helps to improve long-term survival rates for some patients with HCC, it remains an impractical treatment for patients with advanced or late-stage diagnoses. In addition, attempted pharmacological interventions are hindered by the molecular heterogeneity and complex etiology of HCC, often making those interventions ineffective treatment options.
Researchers at the University of California, Davis have developed a new treatment for HCC - using bioengineered RNA molecules to treat advanced liver cancer. This method utilizes biologic let-7c molecules produced and folded into living cells. Unlike conventional let-7c mimics being used clinically now, these molecules better represent higher-order structures, stabilities, bioactivities and safety profiles. In addition, this nano-therapeutic method has proven more effective in controlling tumor progression. It has also resulted in greater tumor reduction and can significantly extend orthotropic HCC survival.
|Patent Cooperation Treaty||Published Application||2019204733||10/24/2019||2018-798|
Additional Patent Pending
Cancer, HCC, Therapy, RNAi, Bioengineered RNA, ncRNA, Carrier, microRNA, Bioengineering, Nanoparticle, Polyplex, Xenograft